Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Non-Current Debt (2016 - 2021)

GT Biopharma (GTBP) has disclosed Non-Current Debt for 10 consecutive years, with $31000.0 as the latest value for Q3 2021.

  • On a quarterly basis, Non-Current Debt changed 0.0% to $31000.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $31000.0, a 0.0% change, with the full-year FY2020 number at $31000.0, changed 0.0% from a year prior.
  • Non-Current Debt was $31000.0 for Q3 2021 at GT Biopharma, roughly flat from $31000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $31000.0 in Q1 2017 to a low of $31000.0 in Q1 2017.
  • A 5-year average of $31000.0 and a median of $31000.0 in 2017 define the central range for Non-Current Debt.
  • Biggest YoY gain for Non-Current Debt was 0.0% in 2017; the steepest drop was 0.0% in 2017.
  • GT Biopharma's Non-Current Debt stood at $31000.0 in 2017, then changed by 0.0% to $31000.0 in 2018, then changed by 0.0% to $31000.0 in 2019, then changed by 0.0% to $31000.0 in 2020, then changed by 0.0% to $31000.0 in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Non-Current Debt are $31000.0 (Q3 2021), $31000.0 (Q2 2021), and $31000.0 (Q1 2021).